Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
Status:
Completed
Trial end date:
2019-12-19
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC)
with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer.